NEO GENOMICS

COMPASS
COMPREHENSIVE ASSESSMENT

COMPASS®

Clear and complete diagnostic solution is the foundation for the best patient care

Diagnostic clarity to start on the right path

1. Personalized approach guided by a single hematopathologist, evaluating all clinical and laboratory information provided.

2. Medically necessary, multi-modal testing to arrive at the right answer, right now. Acute case notification within 24 hours of sample receipt.

3. Final and actionable diagnosis with a summary assessment for every unique patient.

COMPASS



NEO GENOMICS
866.776.5907, option 3

COMPASS®

Client 1630
Sample Hematopathology/Oncology Facility
999 Elm Street, QA
Mars, FL
Phone: (111) 111-1111
Fax: (222) 222-2222
CC 1

Patient Name: **Doe, Jane**
Patient DOB / Sex: **01/01/1950 / F**
Specimen Type: **Bone Marrow**
Body Site: **Bone Marrow**
Specimen ID: **12345**
MRN:
Reason for Referral: **Thrombocytopenia**

Ordering Physician(s): **Pathologist Sample**
Treating Physician(s): **Sample Oncologist, M.D.**
Accession / CaseNo: **418056 / GPS19-000724**
Collection Date: **10/15/2019**
Received Date: **10/16/2019 10:44:00 AM CDT**
Report Date: **10/17/2019 12:15:49 PM EST**

Clinical History:
69-year-old female with a history of thrombocytopenia. Accompanying CBC report, dated 10/14/2019, indicates WBC 5.0 K/uL, RBC 3.27 M/uL, Hgb 9.7 g/dL, HCT 32.5%, MCV 99.4 fL, MCH 29.7 pg, MCHC 29.8 g/dL, RDW 14.5%, platelets 89 K/uL with a differential count of granulocytes 70.7%, lymphocytes 20.1%, monocytes 6.6%, eosinophils 1.2%, basophils 1.4%.

Final Diagnosis:
MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5Q) AND TP53 MUTATION

Comprehensive Assessment
The bone marrow shows prominent dysmegakaryopoiesis, with no increase in blasts. Additional studies show an isolated del(5q) by cytogenetics and a TP53 mutation by the NextGen Sequencing. The CBC shows thrombocytopenia as well as anemia. The findings are diagnostic of a myelodysplastic syndrome with isolated del(5q). While this subtype of MDS is typically associated with a favorable prognosis and response to lenalidomide, the concomitant presence of a TP53 mutation is associated with an increased risk of leukemia transformation and a poorer response to lenalidomide (Jadersten M, et al. J Clin Oncol 2011;29:1971-9). Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome: Cumulative score of 2.5, as determined by 1 point for good cytogenetics, 0 points for <=2% blasts, 1 point for 8-<10 g/dL Hgb, 0.5 points for 50-<100 K/uL platelets, and 0 points for =>0.8 K/uL ANC (Greenberg PL, et al. Blood 2012;120:2454-65).

Morphology
Bone marrow aspirate smears and core biopsy:
Hypercellular bone marrow with dysmegakaryopoiesis and no increase in blasts, consistent with a myelodysplastic syndrome

Flow Cytometry
No definitive immunophenotypic evidence of a monoclonal B-cell, aberrant T-cell, or increased blast population

Cytogenetics
46,XX,del(5)(q13q33)[9]/46,XY[11] ABNORMAL FEMALE KARYOTYPE
Chromosome analysis shows a female karyotype with one ABNORMAL clone(s) showing a deletion of 5q (9/20 cells).

FISH

Chromosome 8:	Not Detected	Chromosome 20:	Not Detected	5q-/-5/+5 tricolor:	DETECTED
7q-/-7 tri:	Not Detected	KMT2A (MLL) (11q23)*:	Not Detected		

FISH analysis for 5p/5q, 7p11/7q31, chromosome 8, KMT2A (MLL) and 20q: ABNORMAL results with 5q-

NeoTYPE™ Myeloid Disorders Profile
TP53; p. E285K **DETECTED**

The right answer, right now

- Actionable diagnosis
- Prepared by a board-certified hematopathologist
- Available for peripheral blood and bone marrow specimens
- Consultation upon request

NeoGenomics is your One Lab for comprehensive answers. COMPASS® is a streamlined, board-certified hematopathologist-guided approach that delivers actionable results for complex malignancies.

COMPASS CHART®

Comprehensive hematopathology assessment and review over time

CHART contains a series of COMPASS or COMPASS Select™ reports, providing a longitudinal evaluation for a wide range of clinical applications, including:

- Monitoring response to therapy
- Determining disease progression
- Evaluating clonal evolution
- Assessing residual disease

COMPASS SELECT

A comprehensive solution for pathologists

COMPASS Select is optimized for pathologists who perform morphologic evaluation locally. Existing results are seamlessly integrated into the assessment, with only further medically necessary tests performed to arrive at a conclusive diagnosis without excess testing.

COMPASS
COMPREHENSIVE ASSESSMENT

The COMPASS family of diagnostic solutions is advancing patient care

>35 hematopathologists on staff

Acute case notification within 24 hours of sample receipt

>15 years of COMPASS experience

Timely and actionable results

COMPASS delivers an unprecedented level of expertise with a broad portfolio of managed care and GPO contracts and flexible billing option.

- Broad portfolio of managed care and GPO contracts
- Flexible billing options

NeoGenomics Laboratories is a specialized oncology reference laboratory providing the latest technologies, testing, partnership opportunities, and interactive education to the oncology and pathology communities. We offer the complete spectrum of diagnostic services in molecular testing, FISH, cytogenetics, flow cytometry, and immunohistochemistry through our nationwide network of CAP-accredited, CLIA-certified laboratories.

NEO GENOMICS

12701 Commonwealth Dr., Suite 9
Fort Myers, FL 33913
Phone: 866.776.5907 | Fax: 239.690.4237
www.neogenomics.com